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Abstract 
Recently, research has focused on bone marrow derived multipotent 
mesenchymal precursor cells (MPC) for their potential clinical use in bone 
engineering. Prior to clinical application, MPC-based treatment concepts need to be 
evaluated in preclinical, immunocompetent, large animal models. Sheep in particular 
are considered a valid model for orthopaedic and trauma related research. However, 
ovine MPC and their osteogenic potential remain poorly characterized. In the present 
study, ex vivo expanded MPC isolated from ovine bone marrow proliferated at a 
higher rate than osteoblasts (OB) derived from tibial compact bone as assessed 
using standard 2D culture. MPC expressed the respective phenotypic profile typical 
for different mesenchymal cell populations (CD14-/CD31-/CD45-
/CD29+/CD44+/CD166+) and showed a multilineage differentiation potential. When 
compared to OB, MPC had a higher mineralization potential under standard 
osteogenic culture conditions and expressed typical markers such as osteocalcin, 
osteonectin and type I collagen at the mRNA and protein level. After 4 weeks in 3D 
culture, MPC constructs demonstrated higher cell density and mineralization, whilst 
cell viability on the scaffolds was assessed >90%. Cells displayed a spindle-like 
morphology and formed an interconnected network. Implanted subcutaneously into 
NOD/SCID mice on type I collagen coated polycaprolactone-tricalciumphosphate 
(mPCL-TCP) scaffolds, MPC presented a higher developmental potential than 
osteoblasts. In summary, this study provides a detailed in vitro characterisation of 
ovine MPC from a bone engineering perspective and suggests that MPC provide 
promising means for future bone disease related treatment applications. 
 
Introduction 
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In general, bone displays a high intrinsic regenerative capacity following insult 
or disease. Therefore, the majority of bone defects and fractures heal 
spontaneously, stimulated by well orchestrated endogenous cell populations and 
micro-environmental cues. Improvements in surgical techniques, implant design and 
peri-operative management have significantly improved treatment outcomes of 
complex fractures and other skeletal defects resulting from high energy trauma, 
disease, developmental deformity, revision surgery, and tumour resection 1-6. 
However, a compromised wound environment, insufficient surgical technique or 
biomechanical instability can lead to formation of large defects with limited 
regeneration potential 7. Such defects pose a major surgical, socio-economical and 
research challenge and can significantly influence patients’ quality of life 8, 9. Over 
the years, bone grafts have advanced as the “gold standard” treatment for bone 
augmentation 1, 2, 10-16. However, the use of autologous bone is associated with 
additional anaesthetic time and personnel required for graft harvesting 12, 14, 17. Often, 
insufficient amounts of graft can be obtained while access to donor sites is limited 12, 
13, 18, 19. Donor site pain, nerve damage or haemorrhage can occur while donor bone 
is predispositioned to failure 4, 12, 13, 20. To circumvent these limiting factors, there has 
been continuous interest in the use of synthetic and naturally derived bone graft 
substitutes during the past decades. More recently, the concept of tissue engineering 
has emerged as an important approach to bone related orthopaedic and trauma 
research. Tissue engineering unites aspects of cellular biology, biomechanical 
engineering, biomaterial sciences and trauma and orthopaedic surgery. Its general 
principle involves the association of cells with a natural or synthetic supporting 
scaffold to produce a three-dimensional, implantable construct.  
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A number of large animal models have been developed to biomechanically 
simulate human in vivo conditions as closely as possible, and to assess the effects 
of implanted bone grafts and tissue engineered constructs on segmental long bone 
defect regeneration. In particular, mature sheep are considered a valuable model for 
human bone turnover and remodelling activity since animals of 7-9 years of age 
show similar bone structure and composition, possess a bodyweight comparable to 
adult humans, and long bone dimensions enabling the use of human implants 21-24. 
However, published fracture and segmental defect models have often used 
considerably younger animals 25. Whilst, sheep are a well recognized animal model 
for bone related research, the molecular and cellular events surrounding fracture and 
bone defect healing remain poorly understood with respect to the recruitment and 
differentiation of osteogenic precursor cell populations.  
 
In the present study, we hypothesized that ovine marrow derived cells of 7-8 year old 
animals are equivalent to those previously described for humans. The aims of the 
project were to isolate, characterize and compare populations of marrow cells 
derived from the iliac crest with cells from compact bone. Initial characterization of 
cell properties, phenotype and genotype was performed using techniques already 
established for human MPC. The potential of ex vivo expanded ovine marrow and 
bone derived cells to produce tissues with properties consistent with those of mature 
bone was further assessed in vitro and in vivo. The purpose of this study was to 
provide a detailed characterisation of ovine MPC and OB prior to their use in a 
preclinical ovine large animal model in order to evaluate bone tissue regeneration 
following implantation of autologous marrow or bone derived cells into surgically 
created tibial bone defects. 
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Materials and Methods  
Isolation of ovine MPC and OB 
Ovine osteoblast explants were obtained from 6-7 year old Merino sheep 
undergoing experimental surgery as approved by the animal ethics committee of the 
Queensland University of Technology, Brisbane, Australia (ethics number 
0700000915). Compact tibial bone samples were collected under sterile conditions, 
minced, washed with PBS (Invitrogen) and vortexed prior to being incubated with 10 
ml 0.25% trypsin/EDTA (Invitrogen) for 3 min at 37°C, 5% CO2. After trypsin 
inactivation with 10 ml low glucose Dulbecco's Modified Eagle Media (DMEM) 
containing 10% foetal bovine serum (FBS) (Invitrogen), samples were washed once 
with PBS and transferred to 175 cm2 tissue culture flasks (Nunc). Samples were 
topped-up with 12 ml of DMEM containing 10% FBS and 1% penicillin/streptomycin. 
Osteoblast outgrowth could be observed after 5-7 days. Cells were expanded to the 
second or third passage for subsequent experiments. 
Bone marrow aspirates were obtained from the iliac crest under general 
anaesthesia. Total bone marrow cells (0.5-1.5 x 107 cells/ml) were plated at a 
density of 1-2 x 107 cells/cm2 in complete medium comprising low glucose DMEM 
supplemented with 10% FBS, 100 U/ml penicillin and 100 µg/ml streptomycin. Cells 
were subsequently plated at a density of 103 cells/cm2. 
 
Flow cytometric analysis 
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Ex vivo expanded populations were used at passage three of culture for 
immunophenotypic analysis. Ex vivo expanded MPC or OB were treated with 
trypsin/EDTA and resuspended in blocking buffer for 30 min. Individual tubes 
containing 1 x 105 cells were incubated with murine monoclonal IgG antibodies 
reactive to either ovine CD14, CD31, and CD45 (Serotec), ovine and human CD29, 
CD44 (Clone H9H11; Division of Haematology, IMVS, Adelaide, SA, Australia), and 
CD166 (BD Biosciences), or isotype matched controls, 1B5 (IgG1), and 1A6.11 
(IgG2b) at a concentration of 10 µg/ml for 1 h on ice. After washing, cells were 
incubated with secondary detection reagents, goat anti-mouse IgG-FITC or IgM-
FITC conjugated antibodies (1:50; Southern Biotechnology Associates, Inc., 
Birmingham, AL) for 45 min on ice. Following washing, samples were analysed using 
a Cytomics FC 500 flow cytometry system (Beckman Coulter). 
 
Cell proliferation assay 
Adherent passage three MPC and OB were seeded in triplicates at 3000/cm2 
in flat bottomed 24-well plates (Nunc) and maintained in 1 ml standard culture 
medium consisting of low glucose DMEM supplemented with 10% FBS for 1, 3, 5 or 
7 days in a humidified atmosphere (37°C, 5% CO2). At each time point, cells were 
washed twice with PBS and stored at -80°C until analysis. For analysis, samples 
were digested overnight with 0.5 mg/ml proteinase K in 1 x TE at 55°C. DNA content 
for 100 μl of each sample in triplicate were measured and quantified using a Quant-
iT PicoGreen dsDNA assay kit according to the protocol supplied by the 
manufacturer (Invitrogen). An equal volume of the Quant-iT PicoGreen aqueous 
working solution was added to each triplicate and incubated for 3 min on a rocking 
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plate. Fluorescence was measured with a Polar Star Optima plate reader (BMG 
Labtech, Offenburg, Germany) at an excitation wavelength of 485 nm and an 
emission wavelength of 520 nm. 
 
CFU-F clonogenic assay 
CFU-F assays were performed as described previously 26 27. Briefly, passage 
two sheep osteoblasts (OB) and bone marrow derived, mesenchymal progenitor 
cells (MPC) were plated at a density of 0.25 x 104 in six-well plates. Cells were 
maintained in low glucose DMEM supplemented with 100 U/ml penicillin G, 100 
μg/ml streptomycin, and 10% or 20% FBS respectively, at 37°C with 5% CO2 for 6 
days. To enumerate colonies, cultures were washed with PBS, fixed in ice cold 
methanol for 15 min, and stained with 0.05% w/v crystal violet in dH2O for 15 min. 
Stained aggregates of greater than 50 cells were scored as CFU-colonies under a 
light microscope (TS100-U, Nikon, Melville, NY). 
 
2D differentiation in vitro 
 
Passage three MPC and OB were seeded in triplicate into 6-well plates 
(Nunc) at a density of 3000 cells/cm2 and expanded in low glucose DMEM/10% FBS 
(Invitrogen) until confluent. Osteogenic induction was then performed over the 
following 28 days using DMEM/10% FBS supplemented with 50 μg/ml ascorbate-2-
phosphate, 10 mM β-glycerophosphate, 0.1 μM dexamethasone (Sigma-Aldrich). 
Controls were cultured in standard expansion medium (DMEM/10% FBS). 
 
Alkaline phosphatase activity 
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At day 14 and 28, ALP enzyme activity was quantified using a colorimetric 
assay. Triplicates were washed with PBS, incubated with 0.1% Triton X in 0.2 M Tris 
buffer at -20°C for 10 min. Cells were harvested and centrifuged at 10000 rpm for 10 
min at 4°C and 100 μl of the cell extraction supernatant was incubated with 125 μl p-
Nitrophenylphosphate (1mg/ml) in 0.2 M Tris buffer (Sigma-Aldrich) in 96 well plates 
(Nunc) and OD was measured after 30 min at 405 nm in a Polar Star Optima plate 
reader. ALP activity was normalized against the sample DNA content determined 
using a Quant-iT PicoGreen dsDNA assay kit (Invitrogen). 
 
Alizarin red staining 
To determine matrix mineralization, at day 14 and 28, triplicate samples were 
washed twice with PBS and fixed with ice cold methanol for 10 min at room 
temperature. Samples were then washed twice with ddH2O and incubated with 1% 
alizarin red s (Sigma-Aldrich) in ddH2O, pH 4.1 for 10 min with gentle shaking. After 
aspiration of the unincorporated dye, samples were washed three times with ddH2O 
and air dried. Stained monolayers were documented using inverted phase 
microscopy (TS100-U, Nikon, Melville, NY). For quantification of staining, 800 μl 10% 
(v/v) acetic acid was added to each well, and the plate incubated at room 
temperature for 30 min with shaking. The monolayer was then scraped from the 
plate with a cell scraper and transferred with 10% (v/v) acetic acid to a 1.5 ml 
microcentrifuge tube. After vortexing for 30 s, the slurry was overlaid with 500 μl 
mineral oil (Sigma-Aldrich), heated to 85°C for 10 min, and transferred to ice for 5 
min. The slurry was then centrifuged at 20,000 x g for 15 min and 500 μl of the 
supernatant was removed to a new 1.5 ml microcentrifuge tube. Then 200 μl of 10% 
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(v/v) ammonium hydroxide was added to neutralize the acid. Aliquots (150 μl) of the 
supernatant were read in triplicate at 405 nm in 96-well format using opaque-walled, 
transparent-bottomed plates (Nunc). Obtained values were normalized against the 
DNA content of separate samples since treatment with acetic acid was expected to 
cause denaturation of DNA.  
 
Immunohistochemistry 
For immunohistochemistry, OB and MPC were cultured on Thermanox 
coverslips to fit 24-well plates (Nunc). Media was removed; samples were washed 
twice with PBS and fixed in 4% paraformaldehyde for 1 h on ice. Cells were then 
permeabilized with 0.1% Triton X in PBS for 5 min and quenched with 0.15 M glycine 
in PBS for 15 min (Sigma-Aldrich). Samples were blocked with 1% BSA (Sigma-
Aldrich) in PBS for 60 min and incubated with primary mouse anti-human type I 
collagen (1:100) (MP Biomedicals, Irvine, CA) and mouse anti-bovine osteocalcin 
(1:500) (Takara Bio Inc., Japan) antibodies in 1% BSA in PBS for 1 h at room 
temperature. Samples were then washed three times with 0.1% BSA in PBS for 5 
min each wash and incubated with a FITC-conjugated goat anti-mouse secondary 
antibody (Invitrogen) at a concentration of 1:200 for 30 min. Cover slips were then 
mounted on glass microscope slides and visualized using a fluorescent microscope 
(TE2000-U, Nikon, Melville, NY). 
 
Total RNA isolation, primer design and qRT-PCR 
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Total RNA was harvested from triplicate wells, from both differentiated and 
control cells, on days 7, 14, 21 and 28. Cells were washed twice with PBS and lysed 
in 1 ml Trizol reagent (Invitrogen) and RNA isolated following the manufacturer’s 
instructions. cDNA was synthesized from 1µg of total RNA using SuperScript III 
(Invitrogen) according to the manufacturer’s instructions. Sheep specific 
oligonucleotides (Geneworks, TheBarton, SA, Australia) were designed according to 
these parameters: 20-30 nt in length; melting temperature 60ºC, +/- 2ºC; at least one 
primer spanning an exon boundary; amplicon length 150 nt, +/- 50 nt; GC content 
between 40 and 60%; and at the 3’ end a C, G, CG or GC. In those cases where an 
Ovis aries mRNA transcripts was not available, a BLAST search was perform on the 
International Sheep Genome Consortium database 
(https://isgcdata.agresearch.co.nz/) using the equivalent human mRNA transcript. To 
date, the exon boundaries of sheep transcript have not been annotated; these 
boundaries were therefore based exon boundary information for human and mouse 
mRNA transcripts. Quantitative RT-PCR was performed on an Applied Biosystems 
7900HT FAST Real Time PCR system (Applied Biosystems, Scoresby, VIC, 
Australia) using a 384-well plate layout; templates and reagents were aliquoted using 
an Eppendorf 5075 epMotion pippeting robot (Quantum Scientific, Murarrie, QLD, 
Australia). The reaction volumes per well were as follows: 5 µl 2X SYBR Green 
(Roche, Castle Hill, NSW, Australia), 1 µl forward and reverse primers at 1 µM final 
concentration, 1 µl water, 2 µl cDNA template diluted 1:10 from stock. The thermo 
cycling conditions were as follows: 1 cycle of 10 min at 95°C for activation of the 
polymerase, 40 cycles of 10 sec at 95°C and 1 min at 60°C for amplification. 
Dissociation curve analysis was carried out to verify the absence of primer dimers 
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and/or non-specific PCR products. The expression of the genes of interest was 
normalized against the GAPDH housekeeping gene. 
 
3D cultures  
Fused deposition modelling was used to fabricate circular mPCL-TCP 
scaffolds of 5 mm diameter and 3 mm thickness. Type I rat tail collagen (Vitrogen 
100, Cohesion, Palo Alto, CA) was lyophilized into the pore space forming a 
microporous mesh throughout the polymer. For 3D cultures, 120.000 ovine MPC or 
OB suspended in 60 µl of basal medium were seeded onto each type I collagen 
coated mPCL-TCP scaffolds and placed in an incubator. After 1 h, 1 ml of medium 
was added to each 24-well. Cell scaffold constructs were cultured in DMEM/20% 
FBS supplemented with 50 μg/ml ascorbate-2-phosphate, 10 mM beta-
glycerophosphate, 0.1 μM dexamethasone on a rocking plate (f=0.125 Hz) for up to 
4 weeks. 
 
SEM 
Cell scaffold constructs were fixed with 3% (v/v) glutaraldehyde in 0.1 M 
sodium cacodylate buffer solution (pH 7.3) for 1 h at 4°C. Fixed specimens were 
then dehydrated through a series of alcohols; two changes each of 50%, 70%, 90%, 
and 100% ethanol and were incubated for 10 min between each change. Specimens 
were then critical point dried (Denton Vacuum, Moorestown, NJ) and gold coated in 
a SC500, Bio-Rad sputter coater (Bio-Rad) before examination using a FEI Quanta 
200 scanning electron microscope (FEI, Hillsboro, OR).  
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Confocal laser microscopy 
To assess cell viability and morphology of MPC and OB seeded onto type I 
collagen coated mPCL-TCP scaffolds, samples were stained with fluorescein 
diacetate (FDA) and propidium iodide (PI)(Invitrogen) or rhodamine conjugated 
phalloidin and 4',6-diamidino-2-phenylindole (DAPI)(Invitrogen). For FDA-PI staining, 
samples were rinsed 3 times with PBS and incubated with FDA staining solution (2 
µg/ml) at 37°C for 15 min in the dark. FDA is a cell-permeant esterase substrate 
which is hydrolysed by living/viable cells to give green fluorescence. Samples were 
then rinsed 3 times with PBS and incubated with PI staining solution (20 µg/ml) at 
room temperature for 2 min in dark. PI is actively excluded by live cells thus dead 
cells in a population are stained red. Samples were again rinsed 3 times with PBS 
and visualised with a Leica SP5 confocal microscope (Leica Microsystems GmbH, 
Wetzlar, Germany). 
For phalloidin-DAPI staining, samples were fixed with 4% paraformaldehyde for 20 
min and permeabilized with 0.2% Triton X-100 in PBS for 20 min at room 
temperature with gentle rocking. Samples were then washed twice for 5 min with 1 
ml PBS at room temperature. 700 µl rhodamine-conjugated phalloidin (0.8 U/ml in 
1% BSA in PBS) was added to each sample and incubated for 1 h at room 
temperature with gentle rocking. Phalloidin binds to F-actin. Samples were then 
washed twice for 5 min with 1 ml PBS at room temperature and nuclei were stained 
with DAPI staining solution (1.0 µg/ml in PBS) for 40-50 min at room temperature. 
Samples were washed twice for 5 min with 1 ml PBS at room temperature and 
visualised with a Leica SP5 confocal microscope. 
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In vivo transplantation studies 
Ovine MPC and OB were seeded onto type I collagen coated mPCL-TCP 
scaffolds at a density of 120.000 cells/scaffold and cultured for 4 weeks in 
DMEM/20% FBS supplemented with 50 μg/ml ascorbate-2-phosphate, 10 mM β-
glycerophosphate, 0.1 μM dexamethasone on a rocking plate (f=0.125 Hz). The cell 
scaffold constructs were then transplanted subcutaneously into both left and right 
side pockets formed in the dorsal surface of 10-week-old immunocompromised 
NOD/SCID mice (ARC, Perth, WA, Australia). Implants were recovered after 8 
weeks and fixed in 4% paraformaldehyde.  
 
µCT analysis  
Micro CT analysis was performed on both the in vitro constructs and the in 
vivo constructs. After 4 weeks of in vitro culture, constructs were carefully removed 
from each well and inserted into polycarbonate sleeves for micro-CT analysis. In 
vitro mineralization within the constructs was quantified using a Micro-CT 40 scanner 
(Scanco Medical, Brüttisellen, Switzerland) at a voxel size of 6 μm. Samples were 
evaluated at a threshold of 72, a filter width of 3.0 and filter support of 5.0. In vivo 
transplanted constructs were scanned at a voxel size of 16 µm and were evaluated 
at a threshold of 140, a filter width of 1.0 and filter support of 2. X-ray attenuation 
was correlated to sample density using a standard curve generated by scanning 
hydroxyapatite phantoms with known mineral density. Mineralized matrix volume or 
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bone volume fraction, and mineral density were quantified throughout the entire 
construct.  
 
Histology  
For histological examination, specimens were fixed in 4% paraformaldehyde, 
and dehydrated using an ethanol gradient (30 min in 70%, 1h in 90%, 95% and 
100% ethanol). The samples were then processed through xylenes for 40 min three 
times, infiltrated with MMA for 3h and embedded in MMA containing 3% PEG. Seven 
micrometre sections were cut with an osteomicrotome (SM2500; Leica 
Microsystems, Wetzlar, Germany), stretched with 70% ethanol onto a polylysine 
coated microscope slide (Lomb Scientific), overlayed with a plastic film and slides 
were clamped together before being dried for 12 h at 60°C. Sections were then 
stained using combined von Kossa and van Giesen 28 stains to visualise the 
mineralised bone and connective tissue respectively.  
 
Image analysis  
Histology sections were quantified using Image J software to quantify the 
amount of mineralisation in a given area of section. Briefly, a JPEG image of the 
entire tissue section was selected, converted to grayscale and a scale bar was 
calibrated onto the image. The entire tissue section area was then calculated by 
segmenting the entire tissue region from the background, and then measuring the 
area. Next, only the mineralised (black) area was segmented from the entire tissue 
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area, and measured. The total mineralised area was then calculated as a percentage 
of the total section area. Six sections were analysed per sample group. 
 
Statistical analysis 
Statistical analysis was carried out using the student’s t test and p values < 0.05 
were considered significant.  
 
Results 
MPC show a higher proliferation rate than OB in vitro  
Cells isolated from ovine bone marrow showed a significantly higher 
proliferative potential after 1,3 and 5 days in culture (p<0.05) when compared to 
ovine tibial osteoblasts as represented by the higher DNA content per 24-well for 
MPC (Fig. 1 A). After 6-7 days both MPC and OB entered a plateau phase indicative 
for contact inhibition of cells reaching confluency (p=0.0502).  
 
MPC and OB exhibit a similar immunophenotype 
Fluorescence-activated cell sorting (FACS) analysis was performed to 
characterise the phenotype of ex vivo expanded ovine bone marrow derived MPC 
and OB. The two cell populations exhibited similar expression patterns for CD29 (β1-
Integrin), CD44, CD166 (ALCAM) and CD14 (LPS-R). CD44 and CD166 have 
previously been identified as markers associated with human bone marrow stromal, 
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adipose, and dental pulp stem cells 26, 29-31.  Importantly, both populations did not 
react with hematopoietic markers CD45 (common leukocyte antigen) and CD31 
(PECAM-1, endothelial) (Fig. 2). 
 
Clonogenic efficiency of MPC 
The mean frequency of CFU-F derived from marrow aspirates was 2.5 ± 0.5 
per 0.25 x 104 mononuclear cells (MNC) in both DMEM/10% FBS and 20% FBS, 
with the incidence of CFU-F forming MSC within the marrow MNC population being 
approximately 0.08-0.12%. The mean frequency of CFU-F derived from tibial bone 
explants was 2 ± 0.6 in DMEM/10% FBS and 1.8 ± 0.7 in DMEM/20% FCS 
respectively (incidence of colony forming cells 0.04-0.12%)(data not shown). 
 
2D differentiation potential of ovine MPC and OB in vitro  
The potential of bone marrow derived MPC to differentiate into osteoblasts 
and of bone derived osteoblasts to secrete a mineralised extracellular matrix was 
investigated by culturing cells in the presence of L-ascorbic-2-phosphate, 
dexamethasone, and β-glycerophosphate 31. After 4 weeks of induction, cultured 
MPC and OB had formed extensive amounts of alizarin red-positive mineral deposits 
throughout the adherent layers. However, OB consistently formed significantly fewer 
mineralized nodules (p<0.05) compared to bone marrow derived cells (Fig. 1 C, Fig. 
3 B and H). Extracellular matrix produced by both MPC and OB stained positive for 
type I collagen and osteocalcin (Fig. 3 C-F and I-L). ALP activity measured at day 14 
and day 28 displayed a typical rise-fall pattern 32, 33 and was significantly increased in 
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osteogenically induced OB and MPC (p<0.05) when compared to their respective 
controls (Fig. 1 B). Under osteogenic conditions a significant increase in type I 
collagen expression of 31% could be observed over the course of 4 weeks for MPCs 
whilst an increase of only 9% was found in the control culture without osteogenic 
supplements (Fig. 4 A). Osteocalcin expression was up-regulated around day 21 and 
further increased towards the end of week 4 (23%, 11% in control)(Fig. 4 C). An 
increase in osteopontin expression could be detected between day 7 and 14 (26%, 
5% in control)(Fig. 4 E). For OB, no significant changes in type I collagen expression 
(5%, 5% in control) were found (Fig. 4 B), only a small increase in osteocalcin (9%, 
6% in control) expression (Fig. 4 D). Osteopontin levels slightly increased between 
day 0 and 7 (12%, 7% in control) to further stay on that level (Fig. 4 F). All 
percentages compare to base level activity on day 0. 
 
3D differentiation potential of MPC and OB in vitro 
 Viability, morphology and osteogenic potential of ovine MPC and OB in a 
three dimensional environment was assessed by FDA/PI staining, phalloidin-DAPI 
staining, SEM, and micro computed tomography. After 28 days of osteogenic 
induction under dynamic conditions, cell viability was assessed >90% (Fig. 5 A and 
D). Phalloidin-DAPI staining (Fig. 5 B and E) and SEM analysis (Fig. 5 C and F) 
revealed elongated, spindle-shaped, osteoblast-like cell morphology for both OB and 
MPC. However, MPC seemed to have proliferated at a higher rate on the type I 
collagen coated mPCL-TCP scaffolds forming a dense, interconnected three 
dimensional network. Micro CT analysis displayed mineral deposition throughout the 
entire thickness of OB and MSC-constructs, compared to control constructs (Fig. 6 
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A-F). Scaffolds seeded with MPC showed a significantly higher mineral volume 
fraction (MVF) compared to scaffolds seeded with OB (p=0.000197) (Fig. 6 G) while 
no significant difference in mineral density could be found between MPC and OB-
constructs (Fig. 6 H).  
 
Differentiation potential of MPC and OB in vivo 
The developmental potential of culture-expanded, ovine MPC and OB was 
assessed in vivo following transplantation into NOD/SCID mice in association with 
type I collagen coated mPCL-TCP scaffolds. Transplants were recovered after 8 
weeks, subjected to micro CT analysis and then processed for histology. Micro CT 
analysis revealed a significantly higher degree of ectopic bone formation for the 
scaffolds seeded with MPC prior to implantation (Bone volume fraction: 20.15%) 
when compared to OB (6.12%) or the respective cell free controls (0.55 %) (Fig. 7 A-
C, M). However, no significant difference could be found with regard to the mineral 
density of newly formed bone matrix (Fig. 7 N). 
 
Histological examination of ectopic explants, using von Kossa staining revealed no 
mineralisation for the control (no cell) constructs (Fig. 7 D,G,J) whereas both MPC 
(Fig. 7 E, H, K) and OB (Fig. 7 F, I, L) seeded mPCL-TCP scaffolds formed 
extensive ectopic bone within the implants, over a course of 8 weeks in vivo. Mineral 
nodules containing calcium, stain black with the von Kossa staining by virtue of silver 
ions (positive charge) binding with the mineralised tissue (negative portion of the 
calcium salt) forming a silver salt which is black in colour. The amount of ectopic 
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bone formed was significantly higher for MPC seeded tissue engineered constructs 
compared with OB-seeded constructs (Fig. 7 O)(p<0.05). Residual mPCL-TCP 
scaffold was evident within all transplants (Fig. 7 D) evidenced by voids in the tissue 
from longitudinal and transverse sectioning of the scaffold struts. The infiltration of 
haematopoietic cells together with associated adipose elements was reminiscent of 
native bone marrow (Fig. 7). The formation of different tissue types within the 
transplanted constructs included mineralised bone (mb), fat (f) and fibrous 
connective tissue (c) with clear blood vessel (bv) formation. The predominantly 
formed tissue type in all both MSC and OB samples however, was bone with mature 
osteocytes enclosed in characteristic lacunae surrounded by the bone extracellular 
matrix. 
 
Discussion 
 Orthopaedic research frequently necessitates the utilisation of large animal 
models. Animal models in bone repair research include representations of normal 
fracture-healing, segmental bone defects, and fracture non-unions 34. The selection 
of a specific animal species as a model system involves the consideration of a 
number of factors. Physiological and pathophysiological analogies are essential in 
respect to the scientific question under investigation. It must be manageable to 
operate and observe a multiplicity of study objects over a relatively short period of 
time 22, 35, 36. Further selection criteria include costs for acquisition and care, animal 
availability, acceptability to society, tolerance to captivity and ease of housing 23. 
Mature sheep and goats possess a bodyweight comparable to adult humans and 
long bone dimensions enabling the use of human implants 21. The mechanical 
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loading environment occurring in sheep is well understood 37, 38. Since no major 
differences in mineral composition 39 are evident and both metabolic and bone 
remodelling rates are akin to humans 40, sheep are considered a valid model for 
human bone turnover and remodelling activity 41 and show comparable bone healing 
potential and bone blood supply 42. On a cellular and molecular level however, sheep 
as a well recognized animal model for bone related research remain poorly 
characterized and understood, and the aim of this study was to begin to address the 
shortfalls in literature on this subject. 
 As described previously, bone marrow aspirates collected from adult sheep 
contain a proportion of CFU-F forming cells with an incidence and morphology highly 
similar to human MSC 27, 31, 43-46. The incidence of ovine CFU-F exceeds those 
described for most other animals, but lie within the normal range reported for human 
bone marrow CFU-F 27, 47-50.  
 To date, there is limited information available on the cell surface characteristics 
of ovine bone marrow derived MPC and bone derived OB. This can mainly be 
attributed to the limited availability of antibodies specific for and cross-reacting with 
equivalent sheep antigens 27, 47, 51. However, to validate sheep as a model system for 
research on a cellular and molecular level, and to provide insight into fundamental 
processes such as haematopoiesis, cell migration and homing, injury repair, 
differentiation, and proliferation, the availability of suitable antibodies plays a key 
role. The cell surface expression profile of ovine MPC and OB showed high and 
uniform levels of cell surface CD29, CD44 and CD166 which have previously been 
identified as markers associated with human bone marrow stromal, adipose, and 
dental pulp cells 26, 29-31. Characteristic for ovine MPC and OB cultures was the 
absence of expression of the endothelial associated adhesion marker CD31 and 
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haematopoietic marker CD45 consistent with expression patterns previously 
described for human bone marrow derived MSC  26, 27.  
When compared to ovine OB isolated from compact tibial bone, the cells 
isolated from the bone marrow showed a higher proliferative potential (Fig. 1 A) 
indicative for immature progenitor cells. Both MPC and OB followed a normal growth 
curve reported for different human cell types consisting of a lag phase followed by a 
log phase of exponential cell growth, ending with a plateau phase in which the 
growth rate declined 52-55. The steeper slope of the MPC growth curve between day 
1 and 3 after seeding results in a higher density of cells before the rate of growth 
begins to decline. A high proliferation capacity is desirable when it comes to the 
application of cell based tissue engineering strategies in preclinical models since 
large cell numbers generated over a relatively short period of time may be required 
for various clinical applications. 
After 28 days of culture under osteogenic conditions both MPC and OB were 
shown to produce mineralized extracellular matrix positive for alizarin red, 
osteocalcin and type I collagen. We showed that MPC and OB can be induced to 
form mineral in culture by treatment with osteogenic medium in vitro. Osteogenic 
medium contains a source of phosphate, ascorbic acid, and dexamethasone in a rich 
medium such as α-MEM containing fetal bovine serum (FBS) 56. In a chelation 
process, alizarin red S forms complexes with calcium and therefore allows 
simultaneous evaluation of mineral distribution and inspection of fine structures by 
phase contrast microscopy. It is particularly versatile in that the dye can be extracted 
from the stained monolayer and readily assayed with low variability and a much 
wider linear detection range than traditional calcium detection methods  57, 58.To 
monitor inorganic phosphate deposition may be problematic due to the high levels of 
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contaminating phosphate associated with other components of the cell and the high 
levels of free phosphate in the cytosol.  
The extracellular matrix produced by ovine MPC and OB was shown to stain 
positive for type I collagen and osteocalcin. Type I type I collagen comprises 
approximately 95% of the entire collagen content of bone and about 80% of the total 
proteins present in bone 59, 60. The increase in type I collagen expression on the 
gene level in MPC and its presence in the extracellular matrix deposited by MPC 
under osteogenic conditions is therefore consistent with osteogenic differentiation 
processes. Osteocalcin is synthesized and secreted by normal maturing osteoblasts. 
It is one of the major non-collagenous bone matrix proteins, with osteocalcin 
comprising 1% to 2% of the total proteins in the skeleton 61. Osteocalcin binds with 
high affinity to hydroxyapatite crystals, the key mineral component of bone, and 
regulates bone crystal formation 62. Osteocalcin can also act as a chemo-attractant in 
the recruitment of osteoblasts and osteoclasts, contributing to the dynamics of new 
bone formation and bone resorption 63. Ducy et al. 64 reported that osteocalcin-null 
mice exhibit increased bone formation without impaired bone resorption, suggesting 
a more complex interaction between recruited osteoblasts and osteoclasts in this 
process. In the MPC cultures, osteocalcin expression was up-regulated around day 
21 and further increased towards the end of week 4 which is consistent with 
osteocalcin being a late osteogenic marker. Osteocalcin protein was additionally 
detected immunohistochemically in the ECM produced by both ovine MPC and OB 
further suggesting a bone like composition. Osteopontin is biosynthesized by a 
variety of tissue types including pre-osteoblasts, osteoblasts, osteocytes, and bone 
marrow cells and is considered an early osteogenic marker and was shown to be up-
regulated in the ovine MPC cultures early during differentiation. It has further been 
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implicated as an important factor in bone remodelling 65. Specifically, research 
suggests it plays a role in anchoring osteoclasts to the mineral matrix of bones 66. 
For the OB, no significant changes in type I collagen expression were found, only a 
small increase in osteocalcin expression. Osteopontin levels increased between day 
0 and 7 and remained at this level. The findings suggest that while MPC undergo a 
differentiation process when supplemented with osteogenic factors, OB – as they are 
mature cells already – very much maintain their gene expression pattern. Alkaline 
phosphatase (ALP) is considered a marker for osteoblastic activity in vitro. ALP 
activity measured at day 14 and 28 displayed a typical rise-fall pattern 32, 33 and was 
significantly increased in osteogenically induced OB and MPC (p<0.05) when 
compared to their respective controls (Fig. 1 B).  
Since the extrapolation from results in 2D to cell behaviour in 3D is rather 
difficult, 3D in vitro cultures of ovine MPC and OB were established on medical 
grade PCL-TCP scaffolds produced via fused deposition modelling. Polymer–
calcium phosphate composites confer favourable mechanical and biochemical 
properties for bone tissue engineering, including strength (ceramic phase), 
toughness and plasticity (polymer phase), more favourable degradation and 
resorption kinetics, and graded mechanical stiffness 67, 68. Results obtained from 3D 
in vitro culture confirmed the findings from 2D differentiation studies with MPC 
demonstrating a higher proliferative and osteogenic potential (Fig. 5 and 6). Micro 
CT analysis revealed no significant difference in matrix mineral density suggesting 
that the MPC had undergone an osteogenic differentiation process towards 
osteoblast like cells actively secreting mineralized matrix.  
 Preliminary analysis of the in vivo osteogenic developmental potential of ovine 
MPC and OB was undertaken by subcutaneous transplantation into immune-
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compromised NOD/SCID mice. Both MPC and OB demonstrated osteogenic 
potential upon transplantation with type I collagen coated mPCL-TCP composite 
scaffolds, as indicated by the presence of extensive deposits of ectopic bone (Fig. 
7). The observation of ectopic bone, fibrous tissue, and haematopoiesis is analogous 
with studies using these scaffolds seeded with porcine bone marrow derived 
progenitor cells 68.  
 
Conclusion 
In summary, in the present study, ovine MPC isolation from bone marrow 
aspirates and the isolation of OB from cortical bone explants have been 
standardized. It was found that ovine MPC exhibit morphological, 
immunophenotypical and multipotential characteristics similar to those in human 
bone marrow derived MPC. The study represents an essential first step towards the 
detailed characterization of ovine MPC and OB in translational studies towards the 
establishment of preclinical in vivo models. However, further studies are required to 
verify the regenerative potential of MPC and OB in vivo. 
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Figure legends 
 
Figure 1: Proliferation capacity, ALP activity and matrix mineralization of MPC and 
OB. When compared to OB, MPC displayed a higher proliferative potential (A). In 
osteogenically induced MPC and OB, ALP activity showed a typical rise fall pattern 
(B). After 28 days of culture in osteogenic media, MPC cultures showed a significant 
higher degree of mineralization (C). 
 
Figure 2: Surface antigen expression for MPC and OB. The two cell populations 
exhibited similar expression patterns for CD29 and CD44. CD166 and CD14 was 
>50% MPC while only low levels were detected on OB. Both populations did not 
react with the hematopoietic markers CD45 and CD31.  
 
Figure 3: Alizarin red, osteocalcin (OC) and type I collagen staining for MPC and OB 
cultures after 28 days. Under osteogenic conditions, both MPC and OB secreted a 
mineralized matrix (B, H) that stained positive for OC (D, J) and type I collagen(F, L).  
 
Figure 4: Quantitative RT-PCR for osteogenic markers. RT-PCR revealed significant 
increases in type I collagenand osteocalcin expression over 4 weeks for MPC under 
osteogenic conditions and an increase in osteopontin expression between day 7 and 
14. For OB, no significant changes in type I collagen, osteopontin and osteocalcin 
expression were found. 
 
Figure 5: SEM, live-dead and phalloidin-DAPI staining of MSC and OB on mPCL-
TCP scaffolds. Cell viability was assessed >90% for both cell types (A and D). 
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Phalloidin-DAPI staining (B and E) and SEM analysis (C and F) revealed elongated, 
spindle-shaped, osteoblast-like cell morphology for both OB and MPC forming a 
dense, interconnected three dimensional network. 
 
Figure 6: µCT analysis of 3D in vitro cultures. µCT displayed mineral deposition 
throughout the entire thickness of all constructs. Scaffolds seeded with MPC (C, D) 
showed a higher mineral volume fraction (MVF) (G) compared to OB seeded (E, F) 
or cell free scaffolds (A, B). No significant difference in mineral density was found 
(H).  
 
Figure 7: Micro CT of in vivo specimens revealed significantly more bone formation 
for MPC compared with OB and control (B, C, A, M). No significant difference in 
mineral density was observed (N). Histology revealed extensive ectopic bone 
formation for MPC and OB (E, F, H, I, K, L). Tissue types: mineralised bone (mb), 
muscle (m) fat (f), blood vessels (bv) and fibrous connective tissue (c).  
 
